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Abstract A randomized, blinded, controlled field trial was conducted during summer 2006
in a northern California, USA, herd of beef cattle to evaluate the efficacy of a recombinant
Moraxella bovoculi cytotoxin subunit vaccine to prevent naturally occurring infectious
bovine keratoconjunctivitis (IBK; pinkeye). A convenience sample comprised of 127 steers
were administered a subcutaneous dose of either adjuvant alone (ISCOM matrices; control
group) or recombinant M. bovoculi cytotoxin carboxy terminus adjuvanted with ISCOM
matrices (MbvA group) and were boostered 21 days later. The steers were examined once
weekly for 15 weeks for evidence of IBK. No significant difference in the cumulative
proportion of corneal ulcerations was detected between groups. Compared to the control
calves, the MbvA vaccinates had significantly higher increases in serum neutralizing titers
to M. bovoculi hemolysin between week 0 and week 6. The prevalence of M. bovis
isolations was higher from ulcerated eyes of calves vaccinated with MbvA as compared to
control calves. Vaccination of calves against the carboxy terminus of M. bovoculi RTX
toxin resulted in significant increases in serum hemolysin neutralizing titers and may
modulate organism type cultured from ulcerated eyes of calves in herds where both M.
bovis and M. bovoculi exist. Use of M. bovoculi antigens alone in vaccines to prevent IBK
may not be beneficial in herds where IBK is associated with both M. bovoculi and M. bovis.
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Introduction
Infectiousbovine keratoconjunctivitis (IBK; pinkeye) is the most common eye disease ofcattle
and is seen worldwide affecting both dairy and beef breeds of cattle. The clinical signs of IBK
include corneal ulceration, corneal edema, ocular pain, photophobia, and lacrimation. In the
worst cases the cornea can rupture leading to permanent blindness. In 1960 the Gram negative
rod Moraxella bovis (M. bovis) was demonstrated to be an etiologic agent of IBK (Henson
and Grumbles 1960). In addition to M. bovis, however, Gram negative cocci have been
isolated with or without M. bovis from cattle with IBK (Elad et al. 1988; Fairlie 1966;P u g h
and Hughes 1971; Spradbrow 1967;W i l c o x1970). Prior to 2007, Gram negative cocci
isolated from eyes of cattle with IBK were likely to be identified as Moraxella ovis,
Moraxella ovis-like, Branhamella ovis,o rBranhamella ovis-like. The isolation and
characterization of a novel species of Moraxella designated Moraxella bovoculi (M. bovoculi)
from ulcerated eyes of beef and dairy calves with IBK has raised the question whether M.
bovis is the only organism that causes IBK (Angelos et al. 2007c).
To date, only isolated studies have reported on the prevalence of M. bovoculi as compared
to M. bovis in IBK-associated corneal ulcers. In one study, bacteria that were cultured from
IBK-associated corneal ulcers were identified as Gram negative cocci in ∼46% of ulcers,
while only ∼21% of ulcers were M. bovis positive (Dueger et al. 2004). Gram negative cocci
from that study were subsequently identified as M. bovoculi (Angelos et al. 2007c). In
another study M. bovoculi without M. bovis was isolated from ∼51% of initial IBK-associated
corneal ulcers; M. bovis without M. bovoculi was isolated from 20% of initial ulcers in that
trial (Angelos et al. 2007b). Moraxella bovoculi has also been isolated from reindeer with
infectious keratoconjunctivitis (Tryland et al. 2009). Despite the presence of M. bovoculi in
IBK-associated ulcers, however, Koch’s postulates have not been established for M. bovoculi
and IBK. In a recently published randomized and blinded field trial, an M. bovoculi
autogenous bacterin was not effective against IBK (Funk et al. 2009). In that study the
commercially prepared M. bovoculi bacterin was composed of 2 isolates made during the
preceding year from the same herd. There are, however, anecdotal reports of reduced IBK in
herds previously vaccinated with M. bovis bacterins when a switch to an M. bovoculi bacterin
is made or when an M. bovoculi bacterin is used in conjunction with an M. bovis bacterin.
Essential proteins of M. bovis that are necessary for pathogenicity include pilin and
cytotoxin (hemolysin, cytolysin). Pili enable M. bovis to adhere to the corneal surface
(Annuar and Wilcox 1985; Moore and Rutter 1989; Ruehl et al. 1993a). The M. bovis
cytotoxin lyses bovine neutrophils, erythrocytes, lymphocytes, and corneal epithelial cells
leading to corneal ulceration (Beard and Moore 1994; Gray et al. 1995; Hoien-Dalen et al.
1990; Kagonyera et al. 1989a; Kagonyera et al. 1989b). The M. bovis cytotoxin (MbxA) is
an RTX (repeats in the structural toxin) toxin (Angelos et al. 2001) that resides within an
RTX operon on a pathogenicity island in M. bovis (Angelos et al. 2003; Hess and Angelos
2006). The M. bovis cytotoxin is conserved between geographically diverse strains
(Angelos and Ball 2007). Moraxella bovoculi possesses a complete RTX operon that
encodes an RTX protein designated MbvA, which has 83% deduced amino acid sequence
identity with MbxA (Angelos et al. 2007a).
PreviousstudieshaveexaminedtheefficacyofpartiallypurifiednativeM. bovis cytotoxin or
recombinant M. bovis cytotoxin to prevent IBK. A partially purified M. bovis cytolysin
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(George et al. 2005). Limitations to large scale production of this partially purified M. bovis
cytolysin vaccine prompted further investigations into recombinant M. bovis cytotoxin
vaccines. In one trial the carboxy terminus of MbxA served as the vaccine antigen (Angelos et
al. 2004); in a subsequent trial, the same carboxy terminus of MbxAwas expressed as a fusion
protein with the amino terminus of M. bovis pilin (Angelos et al. 2007b). In these trials,
reduced occurrences of IBK amongst vaccinates as compared to control calves were reported,
however, the differences between vaccinates and controls were not consistently significant.
The presence of M. bovoculi in cultures of eyes from IBK affected calves was documented in
the 2007 trial and may have negatively affected vaccine efficacy, given that both M. bovis and
M. bovoculi were present in the test herd. The present study was designed to evaluate the
efficacy of recombinant M. bovoculi MbvA to prevent naturally occurring IBK.
Materials and methods
Study population
The study population was a convenience sample of 127 Angus (n=68), Hereford (n=2),
Angus-Hereford cross (n=42), and Hereford cross (n=15) calves aged 4.9–7.1 months old.
Weaning weights of the calves ranged from 159 to 294 kg. The calves were maintained on
mixed grass pastures and were managed as a single cohort at the University of California
Sierra Foothills Field Station, Brown’s Valley, CA, USA. The terrain consisted of Sierra
foothill range pasture that varied from 200–400 meters above sea level. The herd
historically had a high prevalence of IBK of approximately 50% of calves. The trial started
on May 2, 2006 and ended on August 15, 2006. Neither the steers nor dams of these steers
had been vaccinated against IBK. The experimental procedure was approved by the
University of California Institutional Animal Care and Use Committee (# 06-12522).
Pre-enrollment examination and vaccination
Calves were restrained in a hydraulic squeeze chute and each eye was examined grossly for
evidence of preexisting corneal disease. Calves with two normally appearing corneas were
randomlyassignedtoeithera controlorvaccinegroupbyuse of ablockedrandomizationscheme.
On the day of enrollment (day 0) and on day 21 when booster vaccinations were administered,
calves received 2 ml of either immune stimulating complex (ISCOM) matrix adjuvant (control
group) or recombinant M. bovoculi cytotoxin carboxy terminus adjuvanted with ISCOM matrix
(MbvA; vaccine group). The study personnel were blinded as to the contents of the vaccines
that were administered. In addition, on day 0 all calves were vaccinated against respiratory viral
pathogens (Bovi-Shield® Gold 5, Pfizer Animal Health, New York, NY, USA), and on day 14
all calves received a multivalent Clostridium-Mannheimia vaccine (One Shot Ultra™ 8; Pfizer
Animal Health), selenium supplementation (Mu-Se®, Schering-Plough, Union, NJ, USA), and
were dewormed (Dectomax® Pour-On, Pfizer Animal Health).
Post-enrollment examination
Once weekly for 15 weeks each calf was restrained in a hydraulic squeeze chute and both
eyes were examined grossly for the presence of corneal opacification by one of two
examiners blinded as to the vaccine type that calves had been administered. If corneal
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Dacron swab. Such eyes were then stained with fluorescein (Sigma, St. Louis, MO, USA) and
examined with a flashlight to determine if a corneal ulcer was present; if so, the swabs were
furtherprocessedasdescribedbelow.AcornealulcerwasconsideredtobeassociatedwithIBK
unlessitappearedtobemechanicallyinduced(i.e.,thepatternoffluoresceinstainingwaslinear
or stellate), or was present in an eye from which a plant awn was removed. If a mechanically
induced ulcer was still present at the next weekly observation, it was considered to be
associated withIBK,andinsuchcases,that observation daywas countedas the startingday for
the ulcer. Corneal ulcer scores (CUS) were assigned according to the widest ulcer diameter as
measured with a ruler held next to the affected eye: 0=no ulcer; 1=less than or equal to 5 mm;
2=greater than 5 mm; and 3=perforated corneal ulcer. Eyes with ulcers were digitally
photographed(CanonEOSD30,CanonU.S.A.,Inc.,LakeSuccess,NY,USA)witharulerheld
next to the eye for subsequent determination of the corneal ulcer surface area as described
below. Calves with a CUS of 2 or greater were treated once with florfenicol (40 mg/kg
subcutaneously; Nuflor®, Schering-Plough Animal Health). Rubber gloves/aprons were worn
by examiners and were rinsed with 1% chlorhexidine solution between calves to prevent
iatrogenic ocular infections.
Bacterial culturing of ulcerated eyes
Ocular swabs collected from eyes of calves with confirmed ulcers were streaked onto 5%
sheep blood agar plates that were stored at 4°C during transport back to the laboratory;
these plates were subsequently streaked for isolation. Plates were incubated at 35°C for
24 hour and examined for the presence of beta hemolysis. Beta hemolytic colonies were
subcultured and identified using biochemical criteria established for M. bovis (Weyant et al.
1996)o rM. bovoculi (Angelos et al. 2007c).
Vaccine formulation
Growth and propagation conditions of M. bovoculi 237 (ATCC BAA-1259
T=CCUG
52049
T) were performed as previously described (Angelos et al. 2007a). The methods for
cloning and expressing the carboxy terminus (amino acids 590 through 927) of MbvAwere
as described (Angelos et al. 2007a). The recombinant carboxy terminus of MbvA was
purified using a protocol for purifying recombinant M. bovis cytotoxin (Angelos et al.
2003). The final MbvA vaccine was mixed 1:1 with ISCOM matrices that had been
prepared as previously described (Angelos et al. 2004) such that the final vaccine delivered
500 µg of recombinant protein in a 2 ml dose. The ISCOM matrix solution was mixed 1:1
with phosphate buffered saline (PBS; pH 7.4) to prepare the final 2 ml control vaccine dose.
All vaccinations were administered subcutaneously in the neck.
Corneal ulcer surface area measurements
Corneal ulcers in the digital images of ulcerated eyes were traced on a computer tablet
(Wacom Cintiq 15X LCD tablet, Wacom Technology Corporation, Vancouver, WA,USA)
using public domain image analysis software (ImageJ program; available at http://rsbweb.
nih.gov/ij). Magnification differences between photographs were accounted for by
standardizing the scale of each tracing using the ruler in each photograph. The mean of 3
tracings of each ulcer was used to calculate the corneal ulcer surface area measurement; for
data analysis, the square root of the corneal ulcer surface area was used to represent the
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2, an area
corresponding to a 1 mm diameter circle.
Hemolysis neutralization assay
Whole blood was collected by jugular venipuncture into serum separator tubes (Corvac tubes,
Sherwood-Davis & Geck, St. Louis, MO, USA) on day 0, day 42, and day 105. Serum was
harvested and stored at −20°C. Prior to use in hemolysis neutralization assays, serum was heat
inactivated at 56°C for 1 hour. Native cytotoxin in diafiltered retentate derived from culture
supernatant of M. bovoculi 237 was prepared using a previously described method for
preparation of M. bovis cytotoxin (Angelos et al. 2001). The diafiltered retentate containing
native M. bovoculi cytotoxin was stored at −80°C until use in the hemolysis neutralization
assays which were performed as previously described (Angelos et al. 2007b). The final
dilution of M. bovoculi 237 diafiltered retentate in the neutralization assays was 1:16. The
dilution endpoint was defined as the last dilution at which no hemolysis was observed. The
geometric mean of three sample endpoints was used as the final dilution endpoint. For
statistical analyses, the day 0–42 and day 0–105 changes in serum hemolysin neutralizing
titers of nonulcerated calves to native M. bovoculi 237 cytotoxin were evaluated.
Statistical analyses
Baseline differences between groups with respect to age at enrollment/weight at weaning/
day 0 serum hemolysin neutralizing titer and breed were evaluated by the Mann-Whitney
and Pearson chi square tests, respectively. The primary outcome variable that was used to
evaluate vaccine efficacy was the occurrence of IBK in calves as measured by the
cumulative proportion of calves ulcerated at weeks 8 and 15 (cumulative proportion
ulcerated). Additional variables examined included the proportion of calves that required at
least one florfenicol treatment; the median number of days until the first ulcer was
observed; the median surface area measurement of the first ulcer (median SAM for first
ulcer); the median peak surface area measurement of the first ulcer (median peak SAM for
first ulcer); and the median number of days for the first ulcer to heal (CUS=0; median days
to heal for first ulcer). Differences in the cumulative proportion of calves that developed
corneal ulcers and the number of treatments for IBK were evaluated using Pearson chi-
square analysis. Risk ratios with 95% confidence intervals (CI) for developing a first ulcer
were calculated for the adjuvant group versus the MbvA group at weeks 8 and 15. The
Mann-Whitney test was used to evaluate differences between groups with respect to median
days to first ulcer, median SAM for the first ulcer, median peak SAM for the first ulcer,
median days to heal for the first ulcer, and changes in day 0–42 and day 0–105 serum
hemolysin neutralizing titers. To reduce possible influences of acquired immunity due to the
development of IBK, changes in hemolysin neutralizing titers were evaluated in calves that
remained nonulcerated through day 105. A Kaplan-Meier (KM) survival curve was
constructed for the time to first ulcer occurrence; differences between KM curves were
evaluated using the log-rank test. Time to first ulcer was defined as the time of enrollment
(day 0) to the time of first observed IBK-associated ulcer (CUS>0). Prevalence ratios for
the isolation of M. bovis and M. bovoculi were calculated for the MbvA group versus the
adjuvant group. In all comparisons, a value of P<0.05 was considered significant; a 95%
CI that did not include 1.0 was considered significant. Statistical analyses were performed
with SPSS (version 16.0; SPSS Inc., Chicago, IL, USA), and StatCalc (version 3.5.1;
EpiInfo; available at: http://www.cdc.gov/epiinfo/).
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Verification of randomization
No significant differences were detected between the groups with respect to age at
enrollment, calf weaning weight, day 0 serum hemolysin neutralizing titer, and breed: P=
0.63, P=0.142, P=0.91, and P=0.64, respectively.
Efficacy of recombinant MbvA vaccine to prevent IBK
At week 8, the cumulative proportion of ulcerated calves was 0.4 (25/62) and 0.37 (24/65)
in the control and MbvA groups, respectively. At week 15, the cumulative proportion of
ulcerated calves was 0.52 (32/62) and 0.45 (29/65), in the control and MbvA groups,
respectively. The differences in the cumulative proportion of ulcerated calves at week 8 and
week 15 were not significantly different (P=0.69 and 0.43, respectively; Table 1). The risk
for ulcer development in control calves by week 8 was 1.09 times more than that of the
MbvA group calves; 95% CI (0.70, 1.69). The risk for ulcer development in control calves
by week 15 was 1.16 times more than that of the MbvA group calves; 95% CI (0.81, 1.66).
No significant differences between vaccine and control groups were observed with respect
to the proportion of calves requiring at least one nuflor treatment, median SAM of the first
ulcer, median peak SAM for the first ulcer, median days to heal for the first ulcer, or the
median change in weight from weaning to day 105 (Table 1). Kaplan-Meier survival
analysis did not show a significant difference between groups when the times to first ulcer
were examined (P=0.38) (Fig. 1).
Systemic immune response following vaccination
The median change in the day 0–42 serum hemolysin neutralizing titers of nonulcerated
calves was significantly higher in the MbvA group (4.3) versus the control group (0) (P=
0.004) (Table 2). There was no significant difference in the median change in the day 0–105
serum hemolysin neutralizing between nonulcerated calves in the control and MbvA groups
(median=0 for both groups).
Bacterial isolates from initial ulcers
From 61 initial ulcers that developed in calves of the combined vaccine groups, M. bovis
and M. bovoculi were both isolated, however, the predominant organism isolated from
initial ulcers was M. bovis (44 isolations) as compared to M. bovoculi (35 isolations)
(Table 3). Moraxella bovis was 2.88 times more likely to be isolated from ulcers in calves
from the MbvA group than from calves in the control group (P=0.09; Table 4).
Discussion
During this 15 week trial, significant differences in the cumulative proportion of calves that
developed corneal ulcerations were not detected between the group that received a
recombinant M. bovoculi cytotoxin subunit vaccine and a control group of calves that
received the adjuvant (ISCOM) alone. It is possible that a recombinant M. bovoculi
cytotoxin vaccine might be more effective in herds in which a majority of IBK cases are
234 Vet Res Commun (2010) 34:229–239associated with M. bovoculi relative to M. bovis. The sample size in this study was
determined by the availability of steers, and it is possible that a larger sample size may have
increased the chances of finding a significant difference. In order to control for
environmental variables such as plant awns, face flies, and UV radiation that can predispose
to IBK, the control calves and vaccinated calves were pastured as a single group. Herd level
immunity amongst the MbvA vaccinated group, however, may have lowered the power of
this study as the occurrence of IBK in the control calves may have been reduced.
The fundamental question of whether M. bovoculi is a primary pathogen in IBK has not
been answered, and specific conclusions regarding the effectiveness of including
recombinant M. bovoculi antigens in vaccines to prevent IBK remain speculative. The
use of a M. bovoculi autogenous vaccine was recently shown to be ineffective at preventing
Table 1 Vaccine group outcomes assessing vaccine efficacy
Outcome Group
a
Control MbvA
cumulative proportion ulcerated wk 8 0.40 0.37
number of calves ulcerated 25 24
P
b 0.69
cumulative proportion ulcerated wk 15 0.52 0.45
number of calves ulcerated 32 29
P 0.43
proportion requiring at least 1 florfenicol treatment
c 0.37 0.34
total number of calves treated 23 22
P 0.70
median days to first ulcer (min.–max.) 42 (28–98) 42 (28–77)
N3 2 2 9
P 0.70
median SAM (min.–max.) for first ulcer 0.32 (0.11–1.55) 0.34 (0.11–1.22)
N3 2 2 9
P 0.97
median peak SAM (min.–max.) for first ulcer 0.19 (0.11–0.46) 0.16 (0.11–0.4)
N
d,e 11 8
P 0.90
median days (min.–max.) to heal for first ulcer 7 (6–21) 7 (7–14)
N
e 11 8
P 0.57
median weight change (min.–max.) weaning to day
105
31.4 (13.6–58.2) 29.1 (5.5–56.4)
N6 2 6 5
P 0.42
aSample size: control, 62; MbvA, 65
bP values reflect comparisons with the control group
cexpressed as total number calves receiving at least 1 florfenicol treatment/number calves in group
dpeak first ulcer surface areas could not be calculated for 1 calf due to missing photographs
eexcludes treated calves
Vet Res Commun (2010) 34:229–239 235naturally occurring IBK (Funk et al. 2009). In that study the experimental vaccine was a
commercially prepared bacterin composed of two different M. bovoculi strains. It is
possible that limited cross reactivity between the vaccine strains and M. bovoculi in the test
herd during the trial period may have reduced the efficacy of the autogenous bacterin; cell
surface antigens such as pili are considered important determinants in cross reactivity and
protection against M. bovis (Lepper 1988). There are, however, anecdotal reports of
autogenous M. bovoculi bacterins preventing IBK in herds when traditional M. bovis
vaccines are not effective. These reports coupled with the occurrences of corneal ulcers
from which only M. bovoculi can be isolated, as occurred in the present study as well as a
previous study (Angelos et al. 2007b), support a hypothesis that M. bovoculi is important in
IBK pathogenesis. If true, this hypothesis could support the rationale to include M. bovoculi
antigens in IBK vaccines, especially in those herds where IBK has been associated with M.
bovoculi.
Fig. 1 Kaplan-Meier survival function curves of time to first corneal ulcer attributed to infectious bovine
keratoconjunctivitis in cross-bred beef steers vaccinated with a recombinant Moraxella bovoculi cytotoxin
vaccine (MbvA; n=65) or adjuvant alone (control; n=62)
Table 2 Median (min.–max.) changes from day 0–42 and 0–105 in serum hemolysin neutralizing titers of
nonulcerated calves to native M. bovoculi cytotoxin
Vaccine group
control (N=30) MbvA (N=36)
Day 0–42 0.0 (−12.0–10.3) 4.3 (−12.0–28.0)
P
a 0.004
Day 0–105 0.0 (−8.0–12.0) 0.0 (−16.0–12.0)
P 0.608
aP value reflects the comparison with the adjuvant control group using median values (Mann-Whitney test)
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terminal 338 amino acids of MbvA; in total, mbvA encodes a 927 amino acid protein
(Angelos et al. 2007a). Previously, the analogous portion of M. bovis MbxA was
demonstrated to elicit a hemolysis neutralizing antibody response in rabbits (Angelos et
al. 2007a). Based on the results of the present study, it can be concluded that calves respond
similarly against MbvA by mounting a hemolysis neutralizing antibody response. The
increase in neutralizing titer between day 0–42 was significantly higher in nonulcerated
vaccinated calves compared to nonulcerated control group calves. The significant increase,
however, was not maintained for the duration of the trial. Previously when we measured the
change in serum hemolysis neutralizing titer of non-ulcerated calves that were vaccinated
with a recombinant M. bovis pilin-cytotoxin, we identified statistically significant increases
not only in the day 0 to day 42 (3 weeks post booster vaccination) titers, but also in the day
0 to day 126 titers (Angelos et al. 2007b). It is possible that the observed difference in the
duration of immune responsiveness against MbvA versus MbxA in our two studies is
related to the composition of the antigen used in the neutralization assays. In a previous
study that examined the stability of M. bovis cytotoxin (MbxA) prepared as a diafiltered
retentate derived from culture supernatant, both full length MbxA as well as immunore-
active MbxA fragments were identified in the diafiltered retentate (George et al. 2004). It is
possible that during the preparation of M. bovoculi diafiltered retentate used for the
hemolysis neutralization assays, partial length fragments of MbvA were similarly co-
purified along with native MbvA, and that in the neutralization assays, these partial length
fragments, while lacking hemolytic activity, still bound to antibodies against MbvA and
rendered such antibodies unavailable to neutralize full-length native MbvA. It is also
possible that other proteins copurified with MbvA in the diafiltered retentate of M. bovoculi
culture supernatant may have served to promote hemolysis, effectively reducing the
measured titers. In the hemolysis neutralizing assays that were performed in the present
study, the M. bovoculi diafiltered retentate had less hemolytic activity relative to similarly
prepared M. bovis diafiltered retentate that we have prepared for previous studies; as such,
Table 3 Frequency of Moraxella spp. isolations from 61 initial ulcers
Organism Vaccine group Total
control (N=32) MbvA (N=29)
M. bovoculi 93 1 2
M. bovis 11 10 21
M. bovoculi plus M. bovis 91 4 2 3
No Moraxellae isolated 3 2 5
Table 4 Frequency of isolation of M. bovis and prevalence ratio (PR) for the association of M. bovis with
initial ulcers
M. bovis isolated from ulcer Vaccine group PR P
MbvA control
Yes 24 20 2.88 0.094
No 5 12
Total 29 32
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only 1:16. In contrast, the final working dilution of M. bovis diafiltered retentate in the
neutralization assays in our 2007 trial was 1:128 (Angelos et al. 2007b).
It is possible that an immune response against epitopes found in the amino terminus of
the M. bovoculi cytotoxin might improve the efficacy of a recombinant M. bovoculi
cytotoxin vaccine. While no previous studies have examined the effectiveness of full length
recombinant M. bovis cytotoxin to stimulate a hemolysis neutralizing immune response,
one study identified the presence of hemolysis neutralizing epitopes in the amino terminus
of HlyA, the RTX toxin expressed by uropathogenic Escherichia coli (Ji and O’Hanley
1990). As such, a full length recombinant M. bovoculi and/or M. bovis cytotoxin may
improve the efficacy of recombinant Moraxella spp. cytotoxin based vaccine against IBK
as compared to carboxy terminus cytotoxin based vaccines as reported here and in earlier
studies (Angelos et al. 2007b; Angelos et al. 2004).
In this study, the prevalence of M. bovis from cultures of initial ulcers was nearly three
times higher in the MbvA vaccinates compared to the control calves. While this higher
prevalence was not statistically significant, it may have biological significance. In a
previous study that evaluated a recombinant M. bovis pilin-cytotoxin vaccine, we found a
higher prevalence of M. bovoculi in cultures from initial ulcers of calves vaccinated with
two M. bovis antigens: pilin and cytotoxin (Angelos et al. 2007b). Moreover, there was a
higher prevalence of M. bovis in ocular cultures from control calves as compared to M.
bovis pilin-cytotoxin vaccinated calves (Angelos et al. 2007b). In the present study it is
possible that the immune response against M. bovoculi MbvA allowed M. bovis to colonize
the ocular surface more readily or provided some other competitive advantage relative to M.
bovoculi. The potential for a host immune response to alter the expression of different M.
bovis pili was previously suggested (Ruehl et al. 1993b). Additional investigations of the
ocular flora of not only IBK-affected, but also normal healthy eyes of calves are necessary
to help define mechanisms by which vaccination may affect the development of IBK and of
the role that M. bovoculi plays in IBK pathogenesis.
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